MARKET

HZNP

HZNP

Horizon Therapeutics Plc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

109.71
+1.76
+1.63%
After Hours: 109.68 -0.03 -0.03% 18:19 09/17 EDT
OPEN
107.75
PREV CLOSE
107.95
HIGH
109.99
LOW
107.20
VOLUME
1.80M
TURNOVER
--
52 WEEK HIGH
111.70
52 WEEK LOW
66.41
MARKET CAP
24.78B
P/E (TTM)
48.97
1D
5D
1M
3M
1Y
5Y
Horizon Therapeutics Plc (HZNP) EVP, General Counsel Brian K Beeler Sold $3 million of Shares
GuruFocus News · 5h ago
Aerie (AERI) Announces Mixed Data From Dry Eye Disease Study
Zacks.com · 1d ago
Here's Why You Should Retain QIAGEN (QGEN) Stock For Now
Zacks.com · 1d ago
Horizon Therapeutics plc Named One of the 2021 Best Workplaces for Women™ by Fortune and Great Place to Work®
DUBLIN, September 16, 2021--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the 2021 Best Workplaces for Women™ list for the first time by Fortune and Great Place to Work®. The Best Workplaces for Women award spotlights th...
Business Wire · 1d ago
Horizon Therapeutics reports record quarter
Tim Walbert, Horizon Therapeutics Chairman and CEO, joins The Exchange to discuss his company's record run and the non-Covid pharmaceuticals the company is working on.
CNBC.com · 2d ago
3 Reasons Why Horizon Therapeutics (HZNP) Is a Great Growth Stock
Zacks.com · 2d ago
Is Horizon (HZNP) a Great Growth Stock?
Zacks.com · 3d ago
Insider Sell: Horizon Therapeutics Public Ltd
MT Newswires · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HZNP. Analyze the recent business situations of Horizon Therapeutics Plc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HZNP stock price target is 132.84 with a high estimate of 154.03 and a low estimate of 107.00.
EPS
Institutional Holdings
Institutions: 633
Institutional Holdings: 232.99M
% Owned: 103.14%
Shares Outstanding: 225.89M
TypeInstitutionsShares
Increased
211
14.48M
New
73
7.08M
Decreased
157
13.64M
Sold Out
53
1.03M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.40%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/President/Chief Executive Officer/Director
Timothy Walbert
Chief Financial Officer/Executive Vice President
Paul Hoelscher
Chief Human Resource Officer/Executive Vice President
Irina Konstantinovsky
Executive Vice President/Chief Administrative Officer
Barry Moze
Executive Vice President/General Counsel
Brian Beeler
Executive Vice President
Daniel Camardo
Executive Vice President
Geoffrey Curtis
Executive Vice President
Michael DesJardin
Executive Vice President
Vikram Karnani
Executive Vice President
Jeffrey Kent
Executive Vice President
Andy Pasternak
Executive Vice President
Jeffrey Sherman
Executive Vice President
Elizabeth Thompson
Lead Director/Independent Director
Michael Grey
Independent Director
William Daniel
Independent Director
Jeffrey Himawan
Independent Director
Susan Mahony
Independent Director
Gino Santini
Independent Director
James Shannon
Independent Director
H. Thomas Watkins
Independent Director
Pascale Witz
No Data
  • All
  • Financials
  • Insiders
More
About HZNP
Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and the inflammation segment. The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the Company’s research and development (R&D) programs. TEPEZZA is a monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). KRYSTEXXA is an infused medicine for uncontrolled gout. The Company's other orphan segment medicines, RAVICTI, PROCYSBI and ACTIMMUNE, treats serious chronic diseases. The inflammation segment includes PENNSAID 2%, DUEXIS, RAYOS and VIMOVO medicines.

Webull offers kinds of Horizon Therapeutics PLC stock information, including NASDAQ:HZNP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HZNP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HZNP stock methods without spending real money on the virtual paper trading platform.